214 related articles for article (PubMed ID: 24731405)
1. [Radiotherapy plus concomitant systemic therapies for patients with brain metastases from breast cancer].
Cao KI; Kirova YM
Cancer Radiother; 2014 Jun; 18(3):235-42; quiz 246, 249. PubMed ID: 24731405
[TBL] [Abstract][Full Text] [Related]
2. [Systemic treatment of brain metastases from breast cancer: cytotoxic chemotherapy and targeted therapies].
Bachelot T; Le Rhun E; Labidi-Gally I; Heudel P; Gilabert M; Bonneterre J; Pierga JY; Gonçalves A
Bull Cancer; 2013 Jan; 100(1):7-14. PubMed ID: 23305997
[TBL] [Abstract][Full Text] [Related]
3. New insights and emerging therapies for breast cancer brain metastases.
Lim E; Lin NU
Oncology (Williston Park); 2012 Jul; 26(7):652-9, 663. PubMed ID: 22888567
[TBL] [Abstract][Full Text] [Related]
4. Overall survival and the response to radiotherapy among molecular subtypes of breast cancer brain metastases treated with targeted therapies.
Miller JA; Kotecha R; Ahluwalia MS; Mohammadi AM; Chao ST; Barnett GH; Murphy ES; Vogelbaum MA; Angelov L; Peereboom DM; Suh JH
Cancer; 2017 Jun; 123(12):2283-2293. PubMed ID: 28192598
[TBL] [Abstract][Full Text] [Related]
5. Systemic treatment of brain metastases in HER2-positive breast cancer: current status and future directions.
Azim HA; Azim HA
Future Oncol; 2012 Feb; 8(2):135-44. PubMed ID: 22335578
[TBL] [Abstract][Full Text] [Related]
6. [Systemic treatment of brain metastases from breast cancer].
Taillibert S; Conforti R; Bonneterre J; Bachelot T; Le Rhun E; Bernard-Marty C
Cancer Radiother; 2015 Feb; 19(1):36-42. PubMed ID: 25662600
[TBL] [Abstract][Full Text] [Related]
7. Clinical outcomes in patients who received lapatinib plus capecitabine combination therapy for HER2-positive breast cancer with brain metastasis and a comparison of survival with those who received trastuzumab-based therapy: a study by the Anatolian Society of Medical Oncology.
Kaplan MA; Isikdogan A; Koca D; Kucukoner M; Gumusay O; Yildiz R; Dayan A; Demir L; Geredeli C; Kocer M; Arslan UY; Inal A; Akman T; Coskun U; Sener N; Inanc M; Elkiran ET; Ozdemir NY; Durnalı AG; Suner A; Alici S; Tarhan MO; Boruban C; Oksuzoglu B; Urakci Z
Breast Cancer; 2014 Nov; 21(6):677-83. PubMed ID: 23335064
[TBL] [Abstract][Full Text] [Related]
8. Prognostic factors of brain metastases from breast cancer: impact of targeted therapies.
Braccini AL; Azria D; Thezenas S; Romieu G; Ferrero JM; Jacot W
Breast; 2013 Oct; 22(5):993-8. PubMed ID: 23831232
[TBL] [Abstract][Full Text] [Related]
9. Multicenter phase II study of lapatinib in patients with brain metastases from HER2-positive breast cancer.
Lin NU; Diéras V; Paul D; Lossignol D; Christodoulou C; Stemmler HJ; Roché H; Liu MC; Greil R; Ciruelos E; Loibl S; Gori S; Wardley A; Yardley D; Brufsky A; Blum JL; Rubin SD; Dharan B; Steplewski K; Zembryki D; Oliva C; Roychowdhury D; Paoletti P; Winer EP
Clin Cancer Res; 2009 Feb; 15(4):1452-9. PubMed ID: 19228746
[TBL] [Abstract][Full Text] [Related]
10. Treatment of brain metastases from HER-2-positive breast cancer: current status and new concepts.
Bartolotti M; Franceschi E; Brandes AA
Future Oncol; 2013 Nov; 9(11):1653-64. PubMed ID: 24156325
[TBL] [Abstract][Full Text] [Related]
11. Breast cancer brain metastases responding to lapatinib plus capecitabine as second-line primary systemic therapy.
Bergen ES; Berghoff AS; Rudas M; Preusser M; Bartsch R
Anticancer Drugs; 2015 Jun; 26(5):579-81. PubMed ID: 25714248
[TBL] [Abstract][Full Text] [Related]
12. Lapatinib plus capecitabine resolved human epidermal growth factor receptor 2-positive brain metastases.
Glück S; Castrellon A
Am J Ther; 2009; 16(6):585-90. PubMed ID: 19287304
[TBL] [Abstract][Full Text] [Related]
13. Phase II study of a triple combination of oral vinorelbine, capecitabine and trastuzumab as first-line treatment in HER2-positive metastatic breast cancer.
Chan A; Conte PF; Petruzelka L; Tubiana-Mathieu N; Ganju V; Llombart A; Espie M; Majois F; Gil MG; Vaissiere N; Villanova G
Anticancer Res; 2013 Jun; 33(6):2657-64. PubMed ID: 23749924
[TBL] [Abstract][Full Text] [Related]
14. Drug Insight: intracellular inhibitors of HER2--clinical development of lapatinib in breast cancer.
Cameron DA; Stein S
Nat Clin Pract Oncol; 2008 Sep; 5(9):512-20. PubMed ID: 18594499
[TBL] [Abstract][Full Text] [Related]
15. Lapatinib in metastatic breast cancer.
Frenel JS; Bourbouloux E; Berton-Rigaud D; Sadot-Lebouvier S; Zanetti A; Campone M
Womens Health (Lond); 2009 Nov; 5(6):603-12. PubMed ID: 19863462
[TBL] [Abstract][Full Text] [Related]
16. Treatment of brain metastases in patients with HER2+ breast cancer.
Bravo Marques JM
Adv Ther; 2009 Jul; 26 Suppl 1():S18-26. PubMed ID: 19669638
[TBL] [Abstract][Full Text] [Related]
17. [Trastuzumab emtansine in the systemic treatment of HER-2-positive breast cancer brain metastases].
Frenel JS; Bally O; Bourbouloux E; Berton-Rigaud D; Campone M; Bachelot T; Heudel PÉ
Bull Cancer; 2016 May; 103(5):507-10. PubMed ID: 26992855
[No Abstract] [Full Text] [Related]
18. Therapeutic approach to the management of HER2-positive breast cancer metastatic to the brain.
Patil A; Sherbet GV
Cancer Lett; 2015 Mar; 358(2):93-99. PubMed ID: 25529010
[TBL] [Abstract][Full Text] [Related]
19. Complete response of brain metastases from breast cancer overexpressing Her-2/neu to radiation and concurrent Lapatinib and Capecitabine.
Abboud M; Saghir NS; Salame J; Geara FB
Breast J; 2010; 16(6):644-6. PubMed ID: 21070441
[TBL] [Abstract][Full Text] [Related]
20. A phase II study of trastuzumab emtansine in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer who were previously treated with trastuzumab, lapatinib, an anthracycline, a taxane, and capecitabine.
Krop IE; LoRusso P; Miller KD; Modi S; Yardley D; Rodriguez G; Guardino E; Lu M; Zheng M; Girish S; Amler L; Winer EP; Rugo HS
J Clin Oncol; 2012 Sep; 30(26):3234-41. PubMed ID: 22649126
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
